ATE526401T1 - Verfahren zur herstellung von proteinen mit freien cysteinresten - Google Patents

Verfahren zur herstellung von proteinen mit freien cysteinresten

Info

Publication number
ATE526401T1
ATE526401T1 AT00902412T AT00902412T ATE526401T1 AT E526401 T1 ATE526401 T1 AT E526401T1 AT 00902412 T AT00902412 T AT 00902412T AT 00902412 T AT00902412 T AT 00902412T AT E526401 T1 ATE526401 T1 AT E526401T1
Authority
AT
Austria
Prior art keywords
cysteine residue
free cysteine
producing proteins
proteins
soluble proteins
Prior art date
Application number
AT00902412T
Other languages
English (en)
Inventor
George Cox
Daniel Doherty
Mary Rosendahl
Original Assignee
Bolder Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22364893&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE526401(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bolder Biotechnology Inc filed Critical Bolder Biotechnology Inc
Application granted granted Critical
Publication of ATE526401T1 publication Critical patent/ATE526401T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT00902412T 1999-01-14 2000-01-14 Verfahren zur herstellung von proteinen mit freien cysteinresten ATE526401T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11604199P 1999-01-14 1999-01-14
PCT/US2000/000931 WO2000042175A1 (en) 1999-01-14 2000-01-14 Methods for making proteins containing free cysteine residues

Publications (1)

Publication Number Publication Date
ATE526401T1 true ATE526401T1 (de) 2011-10-15

Family

ID=22364893

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00902412T ATE526401T1 (de) 1999-01-14 2000-01-14 Verfahren zur herstellung von proteinen mit freien cysteinresten

Country Status (12)

Country Link
EP (2) EP2305804B1 (de)
JP (3) JP2002534119A (de)
KR (1) KR100731826B1 (de)
CN (1) CN1210400C (de)
AT (1) ATE526401T1 (de)
AU (2) AU775937B2 (de)
BR (2) BR0008759B1 (de)
CA (1) CA2359345A1 (de)
ES (1) ES2373093T3 (de)
IL (3) IL144259A0 (de)
NZ (1) NZ513077A (de)
WO (1) WO2000042175A1 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
IL133974A0 (en) 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US7270809B2 (en) 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
ATE526401T1 (de) 1999-01-14 2011-10-15 Bolder Biotechnology Inc Verfahren zur herstellung von proteinen mit freien cysteinresten
CN1318443C (zh) 2000-05-16 2007-05-30 博尔德生物技术公司 含游离半胱氨酸残基的蛋白重折叠的方法
US20040082765A1 (en) 2000-10-16 2004-04-29 Teruo Nakamura Peg-modified erythropoietin
EP1345628B1 (de) 2000-12-20 2011-04-13 F. Hoffmann-La Roche AG Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
MXPA03005406A (es) * 2000-12-20 2003-09-25 Hoffmann La Roche Conjugados de eritropoyetina.
PA8536201A1 (es) * 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
WO2002055532A2 (en) * 2001-01-11 2002-07-18 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds
WO2002069232A2 (en) * 2001-02-19 2002-09-06 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
HRP20040448A2 (en) * 2001-11-20 2006-02-28 Pharmacia Corporation Method for detecting cells with numerical chromosomal abnormalities
GB2389115B (en) * 2001-12-14 2005-03-16 Asterion Ltd Polypeptide having a plurality of modified growth hormone receptor binding domains of growth hormone
AU2003241279A1 (en) * 2002-03-26 2003-10-13 Biosynexus Incorporated Antimicrobial polymer conjugates
EP1382352A1 (de) * 2002-07-19 2004-01-21 GBF Gesellschaft für Biotechnologische Forschung mbH Bisacyloxypropylcystein-Konjugate und deren Verwendung
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
PA8588901A1 (es) * 2002-11-20 2005-02-04 Pharmacia Corp Conjugados de hormona de crecimiento humana pegilados n-terminales y proceso para su preparacion
RS20050502A (sr) 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polimerni konjugati interferona- beta sa povećanom biološkom aktivnošću
CA2788505C (en) 2003-02-26 2018-09-04 Nektar Therapeutics Polymer-factor viii moiety conjugates
SE526214C2 (sv) * 2003-02-28 2005-07-26 Amersham Biosciences Ab Ett sätt att generera metallkelaterande affinitetsligander
EP2261244A3 (de) 2003-04-15 2011-02-23 Glaxosmithkline LLC Humane IL-18 Substitutionsmutanten und deren Konjugate
EP1641481A4 (de) * 2003-05-30 2008-10-15 Centocor Inc Bildung von neuen erythropoietin-konjugaten unter verwendung von transglutaminase
US20070066519A1 (en) * 2003-07-29 2007-03-22 Ares Trading S.A. Use of human growth hormone in multiple system atrophy
AU2004311796A1 (en) * 2003-12-31 2005-07-21 Centocor, Inc. Novel recombinant proteins with N-terminal free thiol
US7318918B2 (en) 2004-05-19 2008-01-15 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
JP2008511610A (ja) * 2004-08-31 2008-04-17 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー グリセロール分岐のポリエチレングリコール−ヒト成長ホルモン結合体、それらの製造方法及び使用方法
US7632921B2 (en) * 2004-11-12 2009-12-15 Bayer Healthcare Llc Site-directed modification of FVIII
WO2006089228A2 (en) 2005-02-16 2006-08-24 Nektar Therapeutics Al, Corporation Conjugates of an epo moiety and a polymer
BRPI0609809A2 (pt) 2005-05-18 2011-10-11 Maxygen Inc polipeptìdeo isolado ou recombinante, conjugado, composição, polinucleotìdeo isolado ou recombinante, célula hospedeira, vetor, métodos para preparar o polipeptìdeo, para preparar um conjugado, para inibir replicação de um vìrus em células infectadas com o vìrus para reduzir o numero de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna de hcv no soro de um paciente infectado com hcv, para reduzir o nìvel de dna de hbv em soro de um paciente infectado com hbv e para reduzir o nìvel de rna de hiv em soro de um paciente infectado com hiv, e, uso do polipeptìdeo ou do conjugado
KR100694994B1 (ko) 2005-06-13 2007-03-14 씨제이 주식회사 사람 과립구 콜로니 형성인자 동종체
JP5335422B2 (ja) 2005-06-17 2013-11-06 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 少なくとも１つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化
KR100735784B1 (ko) 2005-07-20 2007-07-06 재단법인 목암생명공학연구소 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
KR20090013816A (ko) * 2006-05-24 2009-02-05 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 반감기를 갖는 인자 ⅸ 유사체
EP2102355B1 (de) 2006-12-14 2016-03-02 Bolder Biotechnology, Inc. Proteine und peptide mit langer wirkung sowie verfahren zu ihrer herstellung und verwendung
CN1970572A (zh) 2006-12-21 2007-05-30 北京三元基因工程有限公司 干扰素α突变体及其聚乙二醇衍生物
JP5792951B2 (ja) 2010-12-16 2015-10-14 キヤノン株式会社 振動型アクチュエータの制御装置
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
AU2012262428C1 (en) * 2011-05-27 2018-10-11 Takeda Pharmaceutical Company Limited Therapeutic proteins with increased half-life and methods of preparing same
CN104220097B (zh) * 2011-12-19 2019-08-09 建新公司 促甲状腺激素组合物
CN103184209B (zh) * 2011-12-27 2015-09-16 拜奥生物科技（上海）有限公司 人精氨酸酶和聚乙二醇化人精氨酸酶及其应用
SG11201502511YA (en) * 2012-09-04 2015-05-28 Republic Polytechnic Isolated oligonucleotides, methods and kits for detection, identification and/or quantitation of chikungunya and dengue viruses
US11219690B2 (en) * 2013-12-13 2022-01-11 Novo Nordisk Healthcare Ag Method for thioether conjugation of proteins
EA037749B1 (ru) * 2014-10-29 2021-05-18 Тева Фармасьютикалз Острэйлиа Пти Лтд ВАРИАНТЫ ИНТЕРФЕРОНА 2b
AU2016265677B2 (en) * 2015-05-15 2021-12-09 Medimmune, Llc Improved uricase sequences and methods of treatment
IL257420B (en) 2015-08-12 2022-08-01 Pfizer Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation
PL3350333T3 (pl) 2015-09-17 2022-03-07 Modernatx, Inc. Polinukleotydy zawierające region stabilizujący ogon
CN106924754B (zh) * 2015-12-30 2021-11-09 北京大学 聚氨基酸偶联物
US12385034B2 (en) 2016-06-24 2025-08-12 Modernatx, Inc. Methods and apparatus for filtration
MX2019009372A (es) * 2017-02-08 2019-12-11 Pfizer Produccion a gran escala para cisteinas de anticuerpo protegidas y no protegidas y su uso en la conjugacion de proteinas terapeuticas.
CN111172184A (zh) * 2020-03-10 2020-05-19 大连理工大学 一种基于基因修饰得到人重组干扰素的融合基因、融合蛋白及其制备方法
CN112812963A (zh) * 2021-01-28 2021-05-18 美康生物科技股份有限公司 一种总同型半胱氨酸测试卡
CN115368451B (zh) * 2021-05-19 2025-02-28 浙江工业大学 脂肪链修饰的人粒细胞集落刺激因子衍生物及其制备方法
CN115417917A (zh) * 2021-05-30 2022-12-02 中国科学院上海药物研究所 一种新型冠状病毒疫苗多肽及其纳米乳制剂在预防新冠野毒株和突变株感染中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5016321B1 (de) * 1969-05-10 1975-06-12
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
DE3540076A1 (de) * 1985-11-12 1987-05-14 Boehringer Mannheim Gmbh Verfahren zur stabilisierung von creatinkinase
JPH01132598A (ja) * 1987-10-14 1989-05-25 Pitman Moore Inc 変性剤溶液中に含まれる組換え蛋白質における分子内ジスルフィド結合の生成を促進する方法
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5130418A (en) * 1989-05-02 1992-07-14 California Biotechnology Inc. Method to stabilize basic fibroblast growth factor
US5235043A (en) * 1990-04-06 1993-08-10 Synergen, Inc. Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5837539A (en) † 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
DE4113750A1 (de) * 1991-04-26 1992-10-29 Boehringer Mannheim Gmbh Verbesserung der renaturierung bei der sekretion von disulfidverbrueckten proteinen
EP0604580A1 (de) * 1991-09-19 1994-07-06 Genentech, Inc. Expression in E.Coli von Antikörperfragmenten mit mindestens einem cystein in freier -SH Form. Anwendung in der Herstellung bifunktioneller Antikörper.
WO1993020200A1 (en) † 1992-04-02 1993-10-14 Imperial Cancer Research Technology Limited Modified cells and method of treatment
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
JPH08506095A (ja) * 1992-11-25 1996-07-02 アムジェン ボールダー インコーポレイテッド 改変インシュリン様成長因子
EP0708655A1 (de) 1993-04-07 1996-05-01 Amgen Boulder Inc. Methoden zur Vewendung des insulinartigenWachstumsfaktor-bindendes Proteins
AU685187B2 (en) * 1993-10-29 1998-01-15 Incyte Pharmaceuticals, Inc. Chimeric proteins including protease nexin-1 variants
US6207640B1 (en) * 1994-04-07 2001-03-27 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
EP0756494A1 (de) * 1994-05-24 1997-02-05 Amgen Boulder Inc. Modifizierte insulinähnliche-wachstumsfaktore
SG71728A1 (en) * 1994-07-29 2000-04-18 Innogenetics Nv Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
KR100278597B1 (ko) * 1994-10-13 2001-01-15 스티븐 엠. 오드리 케라티노사이트 성장 인자의 유사체, 이 유사체를 암호하는 핵산 및 그것의 제조방법
AU710309B2 (en) * 1995-05-16 1999-09-16 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
CA2232601A1 (en) * 1995-09-22 1997-03-27 Immunomedics, Inc. Recombinant proteins having multiple disulfide bonds and thiol-substituted conjugates thereof
GB9625640D0 (en) * 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
IL131406A0 (en) * 1997-02-21 2001-01-28 Genentech Inc Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies
IL133974A0 (en) 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
ATE526401T1 (de) 1999-01-14 2011-10-15 Bolder Biotechnology Inc Verfahren zur herstellung von proteinen mit freien cysteinresten
JP2008511610A (ja) 2004-08-31 2008-04-17 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー グリセロール分岐のポリエチレングリコール−ヒト成長ホルモン結合体、それらの製造方法及び使用方法
US9175061B2 (en) 2006-07-07 2015-11-03 Novo Nordisk Health Care Ag Protein conjugates and methods for their preparation
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
EP3019531A4 (de) 2013-07-11 2017-03-15 The California Institute for Biomedical Research Immunglobulinfusionsproteine und zusammensetzungen davon

Also Published As

Publication number Publication date
CN1355842A (zh) 2002-06-26
EP1144613B2 (de) 2020-05-06
EP2305804A1 (de) 2011-04-06
AU2004231217B2 (en) 2008-02-28
JP2010280714A (ja) 2010-12-16
AU2413300A (en) 2000-08-01
JP5517844B2 (ja) 2014-06-11
CA2359345A1 (en) 2000-07-20
IL194483A0 (en) 2011-08-01
IL144259A0 (en) 2002-05-23
JP2014064594A (ja) 2014-04-17
BR0008759A (pt) 2002-08-06
ES2373093T3 (es) 2012-01-31
EP1144613A4 (de) 2002-10-29
KR20020011364A (ko) 2002-02-08
BR122013003013B8 (pt) 2021-07-06
BR0008759B1 (pt) 2014-03-11
WO2000042175A1 (en) 2000-07-20
IL144259A (en) 2009-06-15
JP2002534119A (ja) 2002-10-15
CN1210400C (zh) 2005-07-13
KR100731826B1 (ko) 2007-06-22
BR122013003013B1 (pt) 2015-06-30
EP1144613B1 (de) 2011-09-28
AU775937B2 (en) 2004-08-19
AU2004231217A1 (en) 2004-12-23
NZ513077A (en) 2004-03-26
EP2305804B1 (de) 2015-05-06
EP1144613A1 (de) 2001-10-17

Similar Documents

Publication Publication Date Title
ATE526401T1 (de) Verfahren zur herstellung von proteinen mit freien cysteinresten
ATE367398T1 (de) Verfahren zur rückfaltung von proteinen mit freien cysteinresten
ATE261946T1 (de) Verfahren zur herstellung von thiazolidin
DE60124482D1 (de) Verfahren zur Herstellung von Xylylendiamin
DE3852959D1 (de) Verfahren zur Herstellung von N-substituiertes Amin.
DE69115862D1 (de) Verfahren zur Herstellung von Methacrylsäure
DE69011880D1 (de) Verfahren zur Herstellung von L-Aminosäuren durch Fermentation.
DE69903698D1 (de) Verfahren zur Herstellung von Acrylsäure
DE69021239D1 (de) Verfahren zur Herstellung von ellagischer Säure.
DE68914236D1 (de) Verfahren zur Herstellung von Natriumhyaluronat durch Gärung.
DE69120660D1 (de) Verfahren zur herstellung von aminosäure-salzen
DE50105185D1 (de) Verfahren zur Herstellung von Dithiazolyldisulfiden
DE69131376D1 (de) Verfahren zur Herstellung von doppelt-diffundierten integrierten MOSFET-Zellen
DE59001820D1 (de) Verfahren zur herstellung von indolcarbonsaeurederivaten.
FI895921A0 (fi) Enzymhaemmande aminosyraderivat, foerfarande foer deras framstaellning, dessa innehaollande aemnen och deras anvaendning.
DE60131954D1 (de) Verfahren zur herstellung von 2-hydroxy-4-methylthiobutansäure
DE59004490D1 (de) Verfahren zur Herstellung von alpha-Fluoracrylsäurederivaten.
DE69121028D1 (de) Verfahren zur herstellung von methacrylsäure
DE59402601D1 (de) Verfahren zur Herstellung von in alpha-Stellung durch einen Alkylrest substituierten Aldehyden
DE69001071D1 (de) Verfahren zur herstellung von n-alkyl-carbaminsaeurearylestern.
DE58905141D1 (de) Verfahren zur herstellung von cyclopropancarbonsaeureamid.
DE60133395D1 (de) Verfahren zur herstellung von alpha'-chlorketonen
DE3767764D1 (de) Verfahren zur herstellung von n-acryloyl-alpha-aminosaeuren.
DE58905010D1 (de) Verfahren zur herstellung von 5-chlor-3-chlorsulfonyl-2-thiophencarbonsaeureestern.
DE60032308D1 (de) Verfahren zur Herstellung von Trichloressigsäure

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties